Clinical trial NCT03747614: Ocular Micro-vascular Research Base on Functional Slip Lamp Biomicroscopy
Official title: Ocular Micro-vascular Research Base on Functional Slip Lamp Biomicroscopy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Dry Eye Syndromes
Inflammation
Microvessels
Lead sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
Sponsor class: OTHER
First posted: 2018-11-20
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: subjects from zhongshan ophthalmic center
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: Dry eye disease (DED), as one of the most common ocular surface diseases that affecting visual acuity, is highly associated with ocular surface inflammation. Until now, there is no accurate quantization index system to evaluate real-time ocular surface inflammation. Besides, an individualized therapy for ocular surface inflammation is also badly needed. As we all know, conjunctival congestion is one of the important clinical appearance of ocular surface inflammation. Hence, we suggest that several specific microvascular indexes could measure the change of ocular surface inflammation. Our program is aiming to investigate the correlation between inflammatory factors and blood flow velocity as well as microvascular distribution detecting from bulbar conjunctiva through our own devices and software.Futhermore, we tend to compare ocular surface microvascular indexes and microvascular distribution in normal people and dry eye patients in order to establish a database for Chinese people. By confirming the relationship between ocular surface microvascular indexes and ocular inflammation, we hope to set up new diagnostic criteria for ocular inflammation and an individualized therapeutic regimen based on ocular surface microvascular indexes. Finally, we want to establish a precision diagnostic and therapeutic pattern for dry eye disease.

Detailed description: Dry eye (DE) is a growing public health concern that affects not only the visual function but also the quality of life of patients. In 2017, the International DE Study Workshop (DEWSII) adjusted the definition of DE by particularly emphasizing the inflammation in the ocular surface, and this adjustment represented a major shift in the understanding of dry eye disease (DED) pathogenesis and the facilitation of DED treatment.1,2 The recurrence of chronic and low-grade inflammation plays an important role in long-term disease progression and gradually deteriorates the ocular surface.3 Previous studies have concluded that the inflammatory response is involved in the pathological process of DE.4-7 The concentrations of IL-1α and mature IL-1ß in the tear fluid are increased.4,5 The activity of MMP-9, a suggested biomarker associated with ocular surface diseases including DE, is significantly elevated in Meibomian gland dysfunction (MGD), Sjögren's syndrome (SS) and aqueous tear deficiency (ATD).6 Other studies have indicated that inflammatory mediators such as IL-6, IL-8 and TNFα are expressed proportionally to the severity of DE symptoms, indicating the involvement of inflammation.7 The identification of inflammation as a major factor in DE informs the treatment strategy, including anti-inflammatory medication, which results in improvements to the ocular surface condition and to ocular comfort in DED patients.8,9 A series of studies have demonstrated improvements in the subjective and objective signs and symptoms of DE after anti-inflammatory and immunomodulatory therapies.8-11 To monitor the status of ocular surface inflammation and the ocular surface condition, traditional assessments, namely, evaluation of conjunctival hyperemia12 and corneal fluorescein staining using a slit lamp biomicroscope, are used. However, these methods are subjective and volatile and may not be sensitive indicators of the disease stage and treatment efficacy.13 A number of new tests have been used to distinguish inflammation.13-15 These new technologies include corneal confocal microscopy,15 conjunctival impression cytology16 and inflammatory tear-film cytokine tests in research and in the clinic.17 These newly implemented techniques have several limitations. Corneal confocal microscopy is a structure-based instrument with a narrow view of 400 × 400 µm2 that is limited to localization and cell counting. Conjunctival impression cytology16 and inflammatory tear-film cytokine tests19 are not routinely used, possibly due to the invasiveness, high cost and discomfort of these techniques.5,18 Therefore, the development of new methodologies to noninvasively and subjectively evaluate the inflammation status of the ocular surface is crucial.

The microvascular system of the bulbar conjunctiva can be easily accessed. The release of inflammatory cytokines on the ocular surface can cause vasodilation, which may result in alterations to the conjunctival microcirculation.19 Cheung et al. used a computer-assisted intravital microscope to evaluate vasculopathies of the conjunctival vessels and identified microvascular abnormalities in patients with diabetes20 and in patients who wore contact lens.21 Schulze et al. have also performed 'evaluations of the redness of the bulbar conjunctiva using fractal analysis and photometry.22 However, these studies did not directly measure the microcirculation. The microcirculation is an important aspect of the vascular system, may directly represent the hemodynamic response to ocular surface inflammation and may exhibit more sensitivity for monitoring vascular responses to anti-inflammatory treatment. Recently, Jiang et al. developed a functional slit-lamp biomicroscope that could be used to measure the conjunctival blood flow velocity (BFV) and vessel diameter.23 The goal of the present study was to characterize the microvasculature and microcirculation in the bulbar conjunctiva of DE patients in response to anti-inflammatory treatment.

Eligibility criteria: Inclusion Criteria:

* age ≧ 18 years
* Ocular Surface Disease Index (OSDI) ≧ 12.
* A 5-min Schirmer I test (ST) result showing less than 5 mm of moisture on the strip.
* A noninvasive average tear-film break-up time (NI-avBUT) less than 5 s.

Exclusion Criteria:

* Patients were excluded if they had an eye infection, injury, non-DE ocular inflammation, ocular surgery within the last 6 months, or any concurrent treatment that might interfere with the interpretation of the study results (systemic corticosteroids, immunosuppressive therapy, or hormonal replacement therapy). Patients were also excluded if they had an uncontrolled disease, had a significant illness or were pregnant or lactating.

Primary outcomes:
measure: Conjunctival microvascular blood flow velocity
timeFrame: Baseline
measure: Conjunctival microvascular blood flow velocity
timeFrame: 30 days after commencement of treatment
measure: Conjunctival microvascular blood flow velocity
timeFrame: 60 days after commencement of treatment
measure: Conjunctival microvascular diameter
timeFrame: Baseline
measure: Conjunctival microvascular diameter
timeFrame: 30 days after commencement of treatment
measure: Conjunctival microvascular diameter
timeFrame: 60 days after commencement of treatment
measure: Conjunctival microvascular blood flow rate
timeFrame: Baseline
measure: Conjunctival microvascular blood flow rate
timeFrame: 30 days after commencement of treatment
measure: Conjunctival microvascular blood flow rate
timeFrame: 60 days after commencement of treatment
measure: The hyperemia index
timeFrame: Baseline
measure: The hyperemia index
timeFrame: 30 days after commencement of treatment
measure: The hyperemia index
timeFrame: 60 days after commencement of treatment
Secondary outcomes:
measure: Non-invasived tear-film break-up time
timeFrame: Baseline
measure: Non-invasived tear-film break-up time
timeFrame: 30 days after commencement of treatment
measure: Non-invasived tear-film break-up time
timeFrame: 60 days after commencement of treatment
measure: Corneal Fluorescein Staining
timeFrame: Baseline
measure: Corneal Fluorescein Staining
timeFrame: 30 days after commencement of treatment
measure: Corneal Fluorescein Staining
timeFrame: 60 days after commencement of treatment
measure: Schirmer I test
timeFrame: Baseline
measure: Schirmer I test
timeFrame: 30 days after commencement of treatment
measure: Schirmer I test
timeFrame: 60 days after commencement of treatment
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Wan Chen
state: Guangdong
Study officials:
References: